Y0001442
N-[(cis-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine
European Pharmacopoeia (EP) Reference Standard
Synonym(s):
N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C19H27NO3
CAS Number:
Molecular Weight:
317.42
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
nateglinide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
N-[(cis-4-Isopropylcyclohexyl)carbonyl]-ᴅ-phenylalanine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
F Zheng et al.
Journal of endocrinological investigation, 36(7), 489-496 (2013-01-18)
Recent studies highlight an important role of ghrelin in glucose homeostasis, while the association between ghrelin regulation and glucose fluctuation is unclear. We compared the effects of two postprandial hypoglycemic agents on ghrelin response and determined the contribution of ghrelin
Ranee Chatterjee et al.
American journal of hypertension, 26(6), 723-726 (2013-02-19)
Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium. We analyzed data from the Nateglinide
Jian Zhou et al.
Diabetes technology & therapeutics, 15(6), 481-488 (2013-05-02)
Recent studies have identified postprandial glycemic excursions as risk factors for diabetes complications. This study aimed to compare the effects of nateglinide and acarbose treatments on postprandial glycemic excursions in Chinese subjects with type 2 diabetes. This was a multicenter
E Phielix et al.
Diabetes, obesity & metabolism, 15(10), 915-922 (2013-04-12)
Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here, we examined whether pioglitazone plus nateglinide (PIO) interferes with hepatocellular lipid (HCL) content and/or improves insulin sensitivity in well-controlled non-obese patients with type 2 diabetes mellitus (T2DM). Sixteen patients [body mass
Jatinder Kaur et al.
Journal of medicinal chemistry, 55(17), 7883-7891 (2012-08-25)
A new group of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (13 and 18), 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (14 and 19), or nitrooxyethyl (15 and 20) moiety attached to the carboxylic acid group of the type II antidiabetic drugs nateglinide
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service